Condition: Idiopathic Pulmonary Arterial Hypertension · Heritable Pulmonary Arterial Hypertension · Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo · Sponsor: Vanderbilt University Medical Center
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD
This description comes directly from the study's public registry record.
Kelly Burke, RN · (615) 343-4682 · kelly.burke@vumc.org
Alisha Lindsey, RT · (615) 343-4682 · alisha.lindsey@vumc.org
Always discuss trial participation with your own doctor first.
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05584722